|
1) Wood JM, Maibaum J, Rahuel J, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Comm. 2003; 308: 698-705
|
|
|
|
2) Singh VP, Le B, Khode R, et al Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes. 2008; 57: 3297-306
|
|
|
|
|
|
3) McMurray JJV, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008; 1: 17-24
|
|
|
|
|
|
4) Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009; 119: 530-7
|
|
|
|
|
|
5) Oh B-H, Mitchell J, Herron JR, et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol. 2007; 49: 1157-63
|
|
|
|
|
|
6) Palatini P, Jung W, Shlyakhto W, et al. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irebesartan or ramipril: results of a randomized, double-blind study. J Hum Hypertens. 2010; 24: 93-103
|
|
|
|
|
|
7) Feldman DL, Jin L, Xuan H, et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension. 2008; 52: 130-6
|
|
|
|
|
|
8) Imanishi T, Tsujioka H, Ikejima H, et al. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension. 2008; 52: 563-72
|
|
|
|
|
|
9) Ino J, Kojima C, Osaka M, et al. Dynamic observation of mechanically-injured mouse femoral artery reveals an antiinflammatory effect of renin inhibitor. Arterioscler Thromb Vasc Biol. 2009; 29: 1858-63
|
|
|
|
|
|
10) Cherney DZI, Miller JA, Lai V, et al. Effect of direct renin inhibition on renal hemodynamic function, arterial stiffness, and endothelial function in humans with uncomplicated type 1 diabetes. Diabetes Care. 2010; 33: 361-5
|
|
|
|
|
|
11) Habibi J, Whaley-Connell A, Hayden MR, et al. Renin inhibition attenuates insulin resistance, oxidative stress, and pancrearic remodeling in the transgenic Ren2 rat. Endocrinology. 2008; 149: 5643-53
|
|
|
|
|
|
12) Lastra G, Habibi J, Whaley-Connell AT, et al. Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. Endocrinology. 2009; 150: 2561-8
|
|
|
|
|
|
13) Dong DF, Liu L, Kataoka K, et al. Aliskiren prevents cardiovascular complications and pancrearic injury in a mouse model of obesity and type 2 diabetes. Diabetologia. 2010; 53: 180-91
|
|
|
|
|
|
14) Azizi M, Menard J, Bissery A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol. 2004; 15: 3126-33
|
|
|
|
|
|
15) Stanton A, Jensen C, Nussberger J, et al. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension. 2003; 42: 1137-43
|
|
|
|
|
|
16) Gradman AH, Schmieder RE, Lins RL, et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005; 111: 1012-8
|
|
|
|
|
|
17) Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens. 2007; 20: 11-20
|
|
|
|
|
|
18) Nussberger J, Gradman AH, Schmieder RE, et al. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. Int J Clin Pract. 2007; 61: 1461-8
|
|
|
|
|
|
19) Kushiro T, Itakura H, Abo Y, et al. Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension. Hyper Res. 2009; 32: 169-75
|
|
|
|
|
|
20) Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007; 370: 221-9
|
|
|
|
|
|
21) Sealey JE, Laragh JH. Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises. Am J Hypertens. 2009; 22: 112-21
|
|
|
|
|
|
22) Stanton AV, Dicker P, O'Brien ET. Aliskiren monotherapy results in the greatest and the least blood pressure lowering in patients with high- and low-baseline PRA levels, respectively. Am J Hypertens. 2009; 22: 954-7
|
|
|
|
|
|
23) Anderson K, Weinberger MH, Constance CM, et al. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension. J Renin Angiotensin Aldosterone Syst. 2009; 10: 157-67
|
|
|
|
|
|
24) Nguyen G, Delarue F, Burckle C, et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest. 2002; 109: 1417-27
|
|
|
|
|
|
25) Sakoda M, Ichihara A, Kurauchi-Mito A, et al. Aliskiren inhibits intracellular angiotensin II levels without affecting (pro)renin receptor signals in human podocytes. Am J Hypertens. 2010; 23: 575-80
|
|
|
|
|
|
26) Parving H-H, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008; 358: 2433-46
|
|
|
|
|
|
27) Brenner BM, Cooper ME, deZeeuw D, et al. Effects of losartan on renal and cardiovascular outocomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345: 861-9
|
|
|
|
|
|
28) Fisher ND, Jan Danser AH, Nussberger J, et al. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation. 2008; 117: 3199-205
|
|
|
|
|
|
29) Splenser AE, Fisher NDL, Danser AHJ, et al. Renal plasma flow: glomerular filtration rate relationships in man during direct renin inhibition with aliskiren. J Am Soc Hypertens. 2009; 3: 315-20
|
|
|
|
|
|
30) Duprez DA, Munger MA, Botha J, et al. Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. J Hum Hypertens. 2010; 24: 600-8
|
|
|
|
|
|
31) Scirica BM, Morrow DM, Bode C, et al. Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial. Eur Heart J. 2010; 31: 1993-2005
|
|
|
|
|
|
32) Mann JFE, Schmieder RE, McQueen M, et al. Renal outocomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008; 372: 547-53
|
|
|
|
|
|
33) Ito S, Nakura N, LeBreton S, et al. Efficacy and safety of aliskiren in Japanese hypertensive patients with renal dysfunction. Hypertens Res. 2010; 33: 62-6
|
|
|
|
|